Cyril Abdeddaim

1.1k total citations · 1 hit paper
30 papers, 519 citations indexed

About

Cyril Abdeddaim is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Cyril Abdeddaim has authored 30 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Reproductive Medicine and 6 papers in Surgery. Recurrent topics in Cyril Abdeddaim's work include Ovarian cancer diagnosis and treatment (13 papers), PARP inhibition in cancer therapy (8 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Cyril Abdeddaim is often cited by papers focused on Ovarian cancer diagnosis and treatment (13 papers), PARP inhibition in cancer therapy (8 papers) and Endometrial and Cervical Cancer Treatments (6 papers). Cyril Abdeddaim collaborates with scholars based in France, Italy and United Kingdom. Cyril Abdeddaim's co-authors include Ellie Im, Víctor Moreno, Susana Banerjee, Vanessa Samouëlian, Wei Guo, Jubilee Brown, Adriano Gravina, Ana Oaknin, Hadi Danaee and Cara Mathews and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Cyril Abdeddaim

29 papers receiving 512 citations

Hit Papers

Clinical Activity and Safety of the Anti–Programmed Death... 2020 2026 2022 2024 2020 50 100 150 200
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
    2020 237 citations Cyril Abdeddaim, Susana Banerjee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cyril Abdeddaim France 10 302 184 173 131 92 30 519
Maria-Pilar Barretina-Ginesta Spain 10 243 0.8× 198 1.1× 232 1.3× 84 0.6× 65 0.7× 35 511
Toshiko Minamoto Japan 13 262 0.9× 162 0.9× 130 0.8× 205 1.6× 90 1.0× 34 538
Christopher DiSimone United States 6 271 0.9× 176 1.0× 133 0.8× 60 0.5× 148 1.6× 10 490
Casey Cosgrove United States 14 163 0.5× 363 2.0× 291 1.7× 221 1.7× 62 0.7× 72 681
Mignon-Denise Keyver-Paik Germany 12 255 0.8× 101 0.5× 142 0.8× 33 0.3× 81 0.9× 30 552
Valentina Zanfagnin United States 12 182 0.6× 182 1.0× 223 1.3× 30 0.2× 47 0.5× 24 470
Nicoletta D’Alessandris Italy 14 110 0.4× 329 1.8× 242 1.4× 60 0.5× 76 0.8× 53 487
Paolo Sala Italy 11 218 0.7× 124 0.7× 99 0.6× 147 1.1× 49 0.5× 30 445
Sarper Toker United States 4 354 1.2× 299 1.6× 112 0.6× 61 0.5× 115 1.3× 13 634
Giulia Scaglione Italy 10 106 0.4× 268 1.5× 214 1.2× 51 0.4× 64 0.7× 58 434

Countries citing papers authored by Cyril Abdeddaim

Since Specialization
Citations

This map shows the geographic impact of Cyril Abdeddaim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cyril Abdeddaim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cyril Abdeddaim more than expected).

Fields of papers citing papers by Cyril Abdeddaim

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cyril Abdeddaim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cyril Abdeddaim. The network helps show where Cyril Abdeddaim may publish in the future.

Co-authorship network of co-authors of Cyril Abdeddaim

This figure shows the co-authorship network connecting the top 25 collaborators of Cyril Abdeddaim. A scholar is included among the top collaborators of Cyril Abdeddaim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cyril Abdeddaim. Cyril Abdeddaim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Piffoux, Max, Alexandra Léary, Philippe Follana, et al.. (2025). Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial. Nature Communications. 16(1). 1821–1821. 1 indexed citations
2.
3.
Abdeddaim, Cyril, D.T. Nguyen, P. Gallet, et al.. (2025). First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study. Head & Neck. 47(11). 2939–2949. 1 indexed citations
4.
Freyer, Gilles, Anne Floquet, Olivier Trédan, et al.. (2024). Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications. 15(1). 1985–1985. 13 indexed citations
5.
6.
7.
8.
Kfoury, Maria, Domenica Lorusso, Anne Floquet, et al.. (2023). PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. Gynecologic Oncology. 173. 98–105. 18 indexed citations
9.
10.
Coquan, Elodie, Justine Lequesne, Émeline Colomba, et al.. (2022). 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). International Journal of Gynecological Cancer. 32. A14–A14.
11.
Kfoury, Maria, Domenica Lorusso, Anne Floquet, et al.. (2022). 528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?. Annals of Oncology. 33. S787–S788. 3 indexed citations
12.
Lefèvre‐Arbogast, Sophie, Cyril Abdeddaim, Stéphanie Bécourt, et al.. (2022). The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer. Frontiers in Oncology. 12. 1049970–1049970. 9 indexed citations
13.
Freyer, Gilles, Anne Floquet, Olivier Trédan, et al.. (2021). 733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study. Annals of Oncology. 32. S734–S735. 6 indexed citations
14.
Szturz, Petr, Éva Remenár, Carla M.L. van Herpen, et al.. (2021). Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients. European Journal of Cancer. 156. 109–118. 3 indexed citations
15.
Clatot, Florian, et al.. (2021). Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma. European Journal of Cancer. 159. 125–132. 12 indexed citations
16.
17.
Blanc‐Durand, Félix, Catherine Genestie, Étienne Rouleau, et al.. (2021). Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.. Journal of Clinical Oncology. 39(15_suppl). 5513–5513. 10 indexed citations
18.
Berton, Dominique, Susana Banerjee, Giuseppe Curigliano, et al.. (2021). Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.. Journal of Clinical Oncology. 39(15_suppl). 2564–2564. 29 indexed citations
19.
20.
Fabbro, Michel, Dominique Berton, Justine Lequesne, et al.. (2020). 808MO Paclitaxel with or without pazopanib in ovarian cancer patients with relapse during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study. Annals of Oncology. 31. S611–S612. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria-Pilar Barretina-Ginesta Breakdown of academic impact, for papers by Toshiko Minamoto Breakdown of academic impact, for papers by Christopher DiSimone Breakdown of academic impact, for papers by Casey Cosgrove Breakdown of academic impact, for papers by Mignon-Denise Keyver-Paik Breakdown of academic impact, for papers by Valentina Zanfagnin Breakdown of academic impact, for papers by Nicoletta D’Alessandris Breakdown of academic impact, for papers by Paolo Sala Breakdown of academic impact, for papers by Sarper Toker Breakdown of academic impact, for papers by Giulia Scaglione
Rankless by CCL
2026